The Behavioral and Psychological Symptoms of Dementia in Down Syndrome Scale (BPSD-DS II): Optimization and Further Validation.

Autor:	Dekker AD; Department of Neurology and Alzheimer Center, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands.; Department of Practice-oriented Scientific Research (PWO), Alliade Care Group, Heerenveen, The Netherlands., Ulgiati AM; Department of Neurology and Alzheimer Center, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands.; Department of Practice-oriented Scientific Research (PWO), Alliade Care Group, Heerenveen, The Netherlands., Groen H; Department of Epidemiology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands., Boxelaar VA; Center for Information Technology, University of Groningen, Groningen, The Netherlands., Sacco S; Institut Jérôme Lejeune, Paris, France., Falquero S; Institut Jérôme Lejeune, Paris, France., Carfi A; Department of Geriatrics, Fondazione Policlinico Universitario Gemelli IRCCS, Rome, Italy., di Paola A; Department of Geriatrics, Fondazione Policlinico Universitario Gemelli IRCCS, Rome, Italy., Benejam B; Barcelona Down Medical Center, Fundació Catalana Síndrome de Down, Barcelona, Spain., Valldeneu S; Memory Unit and Biomedical Research Institute Sant Pau (IIB Sant Pau), Department of Neurology, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain.; Centro de Investigación Biomédica en Red en Enfermedades Neurodegenerativas (CIBERNED), Madrid, Spain., Fopma R; Department of Practice-oriented Scientific Research (PWO), Alliade Care Group, Heerenveen, The Netherlands., Oosterik M; Aveleijn, Borne, The Netherlands., Hermelink M; De Twentse Zorgcentra, Enschede, The Netherlands., Beugelsdijk G; Ipse de Bruggen, Nieuwveen/Nootdorp, The Netherlands., Schippers M; Ipse de Bruggen, Nieuwveen/Nootdorp, The Netherlands., Henstra H; Nieuw Woelwijck, Sappemeer, The Netherlands., Scholten-Kuiper M; Philadelphia Zorg, Amersfoort, The Netherlands., Willink-Vos J; Severinus, Veldhoven, The Netherlands., de Ruiter L; Sherpa, Baarn, The Netherlands., Willems L; Sprank, Zwolle, The Netherlands., Loonstra-de Jong A; Vanboeijen, Assen, The Netherlands., Coppus AMW; Department of Primary and Community Care, Radboud University Medical Center, Nijmegen, The Netherlands.; Dichterbij, Gennep, The Netherlands., Tollenaere M; Laboratory of Neurochemistry and Behavior, Department of Biomedical Sciences and Institute Born-Bunge, University of Antwerp, Antwerp, Belgium.; Department of Neurology and Memory Clinic, Hospital Network Antwerp (ZNA) Middelheim and Hoge Beuken, Antwerp, Belgium., Fortea J; Barcelona Down Medical Center, Fundació Catalana Síndrome de Down, Barcelona, Spain.; Memory Unit and Biomedical Research Institute Sant Pau (IIB Sant Pau), Department of Neurology, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain.; Centro de Investigación Biomédica en Red en Enfermedades Neurodegenerativas (CIBERNED), Madrid, Spain., Onder G; Department of Cardiovascular, Endocrine-metabolic Diseases and Aging, Istituto Superiore di Sanitá, Rome, Italy., Rebillat AS; Institut Jérôme Lejeune, Paris, France., Van Dam D; Department of Neurology and Alzheimer Center, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands.; Laboratory of Neurochemistry and Behavior, Department of Biomedical Sciences and Institute Born-Bunge, University of Antwerp, Antwerp, Belgium., De Deyn PP; Department of Neurology and Alzheimer Center, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands.; Laboratory of Neurochemistry and Behavior, Department of Biomedical Sciences and Institute Born-Bunge, University of Antwerp, Antwerp, Belgium.; Department of Neurology and Memory Clinic, Hospital Network Antwerp (ZNA) Middelheim and Hoge Beuken, Antwerp, Belgium.
Jazyk:	angličtina
Zdroj:	Journal of Alzheimer's disease : JAD [J Alzheimers Dis] 2021; Vol. 81 (4), pp. 1505-1527.
DOI:	10.3233/JAD-201427
Abstrakt:	Background: People with Down syndrome (DS) are at high risk to develop Alzheimer's disease dementia (AD). Behavioral and psychological symptoms of dementia (BPSD) are common and may also serve as early signals for dementia. However, comprehensive evaluation scales for BPSD, adapted to DS, are lacking. Therefore, we previously developed the BPSD-DS scale to identify behavioral changes between the last six months and pre-existing life-long characteristic behavior. Objective: To optimize and further study the scale (discriminative ability and reliability) in a large representative DS study population. Methods: Optimization was based on item irrelevance and clinical experiences obtained in the initial study. Using the shortened and refined BPSD-DS II, informant interviews were conducted to evaluate 524 individuals with DS grouped according to dementia status: no dementia (DS, N = 292), questionable dementia (DS + Q, N = 119), and clinically diagnosed dementia (DS + AD, N = 113). Results: Comparing item change scores between groups revealed prominent changes in frequency and severity for anxious, sleep-related, irritable, restless/stereotypic, apathetic, depressive, and eating/drinking behavior. For most items, the proportion of individuals displaying an increased frequency was highest in DS + AD, intermediate in DS + Q, and lowest in DS. For various items within sections about anxious, sleep-related, irritable, apathetic, and depressive behaviors, the proportion of individuals showing an increased frequency was already substantial in DS + Q, suggesting that these changes may serve as early signals of AD in DS. Reliability data were promising. Conclusion: The optimized scale yields largely similar results as obtained with the initial version. Systematically evaluating BPSD in DS may increase understanding of changes among caregivers and (timely) adaptation of care/treatment.
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu